| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 28 Sep 2026 |
8-K: Other Events
On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 |
| 20 Jul 2026 |
8-K: Other Events
On July 18, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (“wet AMD”) population. |
| 29 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On June 24, 2026 (the “Closing Date”), 4D Molecular Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Hercules Capital, Inc. (“Hercules”), providing for term loans in an aggregate princi... |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually via the internet. On April 20, 2026, the record date for the meeting, there were 52,274,735 s... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 |
| 30 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 25, 2026, the Board of Directors of 4D Molecular Therapeutics, Inc. (the “Company”) appointed Kristian Humer as the Company’s Principal Accounting Officer, effective immediately. In this role, Mr. Humer succeeds Ashoo Gupta, who... |
| 18 Mar 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027 |
| 26 Jan 2026 |
8-K: Unregistered Sales of Equity Securities
4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder... |
| 07 Jan 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
As of December 31, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) estimates that it had approximately $514 million in cash, cash equivalents and marketable securities. This estimate of its cash, cash equivalents and marketable sec... |
| 10 Dec 2025 |
8-K: Other Events
On December 10, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) announced its intention to implement protocol amendments (the “Amendments”) to the 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials of 4D-150 in wet AMD (the “4FRONT Tria... |
| 17 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive at least $50 million from cost sharing |
| 07 Nov 2025 |
8-K: Other Events
As representatives (the “Representatives”) of the several Underwriters |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition; Other Events
As of September 30, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) estimates that it had approximately $372.2 million in cash, cash equivalents and marketable securities. This estimate of its cash, cash equivalents and marketable ... |
| 31 Oct 2025 |
8-K: Entry into a Material Definitive Agreement
On October 31, 2025, 4D Molecular Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”). Pursuant to the Agreement, the Company granted Ots... |
| 02 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year
(Adopted December 4, 2020)(Effective as of December 15, 2020, as amended on June 14, 2022, November 16, 2023 and September 30, 2025) |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedule |
| 02 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
On June 27, 2025, Uneek Mehra informed 4D Molecular Therapeutics, Inc. (the “Company”) of his intent to resign as Chief Financial and Business Officer of the Company effective as of July 15, 2025 in order to pursue other opportunities. |
Loading...